RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Endothelial cell markers from clinician's perspective

Authorized Users Only
2017
Authors
Rakocević, Jelena
Orlić, Dejan
Mitrović-Ajtić, Olivera
Tomašević, Miloje
Dobrić, Milan
Zlatić, Nataša
Milašinović, Dejan
Stanković, Goran
Ostojić, Miodrag
Labudovic-Borović, Milica
Article (Published version)
Metadata
Show full item record
Abstract
Endothelial cell markers are membrane-bound or cytoplasmic molecules expressed by endothelial cells, which help their easier identification and discrimination from other cell types. During vasculogenesis, endothelial cells differentiate from hemangioblasts to form new blood vessels. With the discovery of endothelial progenitor cells (EPC) and their ability to form new blood vessels, the term vasculogenesis is not only reserved for the embryonic development. Possibility of de novo blood vessel formation from EPC is now widely explored in different ischemic conditions, especially in cardiovascular medicine. Numerous clinical trials have tested enhancing tissue vascularization by delivering hematopoietic cells that expressed endothelial markers. This therapeutic approach proved to be challenging and promising, particularly for patients who have exhausted all conventional therapeutic modalities. Angiogenesis, which refers to the formation of new blood vessels from existing vasculature, is ...indispensable process during tumor progression and metastasis. Blockage of tumor angiogenesis by targeting and inhibiting endothelial cell has emerged as novel safe and efficacious method to control many advanced malignant diseases. Numerous clinical studies are currently testing new antiangiogenic drugs which target and inhibit endothelial cell markers, receptors or molecules which transmit receptor-mediated signals, therefore inhibiting endothelial cell proliferation, migration and vascular tube formation. Many of these drugs are now widely used in clinical settings as first-or second-line chemotherapy in advanced malignant conditions. So far, these therapeutic approaches gave modest, yet encouraging clinical improvements, prolonging survival and improving functional capacity and quality of life for many terminally ill patients. Here we present the most commonly used endothelial cell markers along with their applicability in contemporary clinical practice.

Keywords:
Endothelial cell / Surface marker / CD34 / CD31 / VEGF / VEGFR2
Source:
Experimental & Molecular Pathology, 2017, 102, 2, 303-313
Publisher:
  • Academic Press Inc Elsevier Science, San Diego

DOI: 10.1016/j.yexmp.2017.02.005

ISSN: 0014-4800

PubMed: 28192087

WoS: 000403040200021

Scopus: 2-s2.0-85014539011
[ Google Scholar ]
52
40
URI
http://rimi.imi.bg.ac.rs/handle/123456789/821
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Rakocević, Jelena
AU  - Orlić, Dejan
AU  - Mitrović-Ajtić, Olivera
AU  - Tomašević, Miloje
AU  - Dobrić, Milan
AU  - Zlatić, Nataša
AU  - Milašinović, Dejan
AU  - Stanković, Goran
AU  - Ostojić, Miodrag
AU  - Labudovic-Borović, Milica
PY  - 2017
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/821
AB  - Endothelial cell markers are membrane-bound or cytoplasmic molecules expressed by endothelial cells, which help their easier identification and discrimination from other cell types. During vasculogenesis, endothelial cells differentiate from hemangioblasts to form new blood vessels. With the discovery of endothelial progenitor cells (EPC) and their ability to form new blood vessels, the term vasculogenesis is not only reserved for the embryonic development. Possibility of de novo blood vessel formation from EPC is now widely explored in different ischemic conditions, especially in cardiovascular medicine. Numerous clinical trials have tested enhancing tissue vascularization by delivering hematopoietic cells that expressed endothelial markers. This therapeutic approach proved to be challenging and promising, particularly for patients who have exhausted all conventional therapeutic modalities. Angiogenesis, which refers to the formation of new blood vessels from existing vasculature, is indispensable process during tumor progression and metastasis. Blockage of tumor angiogenesis by targeting and inhibiting endothelial cell has emerged as novel safe and efficacious method to control many advanced malignant diseases. Numerous clinical studies are currently testing new antiangiogenic drugs which target and inhibit endothelial cell markers, receptors or molecules which transmit receptor-mediated signals, therefore inhibiting endothelial cell proliferation, migration and vascular tube formation. Many of these drugs are now widely used in clinical settings as first-or second-line chemotherapy in advanced malignant conditions. So far, these therapeutic approaches gave modest, yet encouraging clinical improvements, prolonging survival and improving functional capacity and quality of life for many terminally ill patients. Here we present the most commonly used endothelial cell markers along with their applicability in contemporary clinical practice.
PB  - Academic Press Inc Elsevier Science, San Diego
T2  - Experimental & Molecular Pathology
T1  - Endothelial cell markers from clinician's perspective
EP  - 313
IS  - 2
SP  - 303
VL  - 102
DO  - 10.1016/j.yexmp.2017.02.005
UR  - conv_4039
ER  - 
@article{
author = "Rakocević, Jelena and Orlić, Dejan and Mitrović-Ajtić, Olivera and Tomašević, Miloje and Dobrić, Milan and Zlatić, Nataša and Milašinović, Dejan and Stanković, Goran and Ostojić, Miodrag and Labudovic-Borović, Milica",
year = "2017",
abstract = "Endothelial cell markers are membrane-bound or cytoplasmic molecules expressed by endothelial cells, which help their easier identification and discrimination from other cell types. During vasculogenesis, endothelial cells differentiate from hemangioblasts to form new blood vessels. With the discovery of endothelial progenitor cells (EPC) and their ability to form new blood vessels, the term vasculogenesis is not only reserved for the embryonic development. Possibility of de novo blood vessel formation from EPC is now widely explored in different ischemic conditions, especially in cardiovascular medicine. Numerous clinical trials have tested enhancing tissue vascularization by delivering hematopoietic cells that expressed endothelial markers. This therapeutic approach proved to be challenging and promising, particularly for patients who have exhausted all conventional therapeutic modalities. Angiogenesis, which refers to the formation of new blood vessels from existing vasculature, is indispensable process during tumor progression and metastasis. Blockage of tumor angiogenesis by targeting and inhibiting endothelial cell has emerged as novel safe and efficacious method to control many advanced malignant diseases. Numerous clinical studies are currently testing new antiangiogenic drugs which target and inhibit endothelial cell markers, receptors or molecules which transmit receptor-mediated signals, therefore inhibiting endothelial cell proliferation, migration and vascular tube formation. Many of these drugs are now widely used in clinical settings as first-or second-line chemotherapy in advanced malignant conditions. So far, these therapeutic approaches gave modest, yet encouraging clinical improvements, prolonging survival and improving functional capacity and quality of life for many terminally ill patients. Here we present the most commonly used endothelial cell markers along with their applicability in contemporary clinical practice.",
publisher = "Academic Press Inc Elsevier Science, San Diego",
journal = "Experimental & Molecular Pathology",
title = "Endothelial cell markers from clinician's perspective",
pages = "313-303",
number = "2",
volume = "102",
doi = "10.1016/j.yexmp.2017.02.005",
url = "conv_4039"
}
Rakocević, J., Orlić, D., Mitrović-Ajtić, O., Tomašević, M., Dobrić, M., Zlatić, N., Milašinović, D., Stanković, G., Ostojić, M.,& Labudovic-Borović, M.. (2017). Endothelial cell markers from clinician's perspective. in Experimental & Molecular Pathology
Academic Press Inc Elsevier Science, San Diego., 102(2), 303-313.
https://doi.org/10.1016/j.yexmp.2017.02.005
conv_4039
Rakocević J, Orlić D, Mitrović-Ajtić O, Tomašević M, Dobrić M, Zlatić N, Milašinović D, Stanković G, Ostojić M, Labudovic-Borović M. Endothelial cell markers from clinician's perspective. in Experimental & Molecular Pathology. 2017;102(2):303-313.
doi:10.1016/j.yexmp.2017.02.005
conv_4039 .
Rakocević, Jelena, Orlić, Dejan, Mitrović-Ajtić, Olivera, Tomašević, Miloje, Dobrić, Milan, Zlatić, Nataša, Milašinović, Dejan, Stanković, Goran, Ostojić, Miodrag, Labudovic-Borović, Milica, "Endothelial cell markers from clinician's perspective" in Experimental & Molecular Pathology, 102, no. 2 (2017):303-313,
https://doi.org/10.1016/j.yexmp.2017.02.005 .,
conv_4039 .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB